Expertise in
5
conditions

Dr. Naoto T. Ueno

Oncology
University Clinical Education And Research Associates
1319 Punahou St, 
Honolulu, HI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
5
conditions
University Clinical Education And Research Associates
1319 Punahou St, 
Honolulu, HI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Naoto Ueno is an Oncologist in Honolulu, Hawaii. Dr. Ueno is highly rated in 5 conditions, according to our data. His top areas of expertise are Inflammatory Breast Cancer, Breast Cancer, Triple-Negative Breast Cancer, and Bone Tumor. Dr. Ueno is currently accepting new patients.

His clinical research consists of co-authoring 400 peer reviewed articles and participating in 25 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
The Queens Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

UNIVERSITY CLINICAL EDUCATION AND RESEARCH ASSOCIATES
1319 Punahou St, Honolulu, HI 96826

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Inflammatory Breast Cancer (IBC) Registry
Inflammatory Breast Cancer (IBC) Registry
Enrollment Status: Recruiting
Publish Date: October 08, 2024
Intervention Type: Other, Procedure
A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen for Newly Diagnosed Primary Triple-Negative Inflammatory Breast Cancer
A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen for Newly Diagnosed Primary Triple-Negative Inflammatory Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Biological, Drug, Other
Study Drugs: Carboplatin, Paclitaxel, Panitumumab
Study Phase: Phase 2
Phase Ib/II Study of EPA-Based EphA2 Targeted Therapy for Patients With Metastatic Triple-Negative Inflammatory Breast Cancer
Phase Ib/II Study of EPA-Based EphA2 Targeted Therapy for Patients With Metastatic Triple-Negative Inflammatory Breast Cancer
Enrollment Status: Terminated
Publish Date: October 03, 2025
Intervention Type: Drug, Dietary supplement
Study Drug: Dasatinib
Study Phase: Phase 1/Phase 2
A Phase II Study of Anti-PD-1 (MK-3475) Therapy in Patients With Metastatic Inflammatory Breast Cancer (IBC) or Non-IBC Triple Negative Breast Cancer (TNBC) Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
A Phase II Study of Anti-PD-1 (MK-3475) Therapy in Patients With Metastatic Inflammatory Breast Cancer (IBC) or Non-IBC Triple Negative Breast Cancer (TNBC) Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2025
Intervention Type: Other, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
Phase Ib/II Study of Grapiprant (IK-007) and Eribulin Combination Treatment for Metastatic Inflammatory Breast Cancer (mIBC)
Phase Ib/II Study of Grapiprant (IK-007) and Eribulin Combination Treatment for Metastatic Inflammatory Breast Cancer (mIBC)
Enrollment Status: Terminated
Publish Date: June 13, 2025
Intervention Type: Drug
Study Drugs: Eribulin Mesylate, Grapiprant
Study Phase: Phase 1/Phase 2
Enhancing Immunotherapy by Targeting the EGFR Pathway in Inflammatory Breast Cancer: A Phase II Study of Panitumumab (PmAb) and Pembrolizumab (Pembro) in Combination With Neoadjuvant Chemotherapy (NAC) in Patients With Newly Diagnosed Triple Negative Inflammatory Breast Cancer (TN-IBC)
Enhancing Immunotherapy by Targeting the EGFR Pathway in Inflammatory Breast Cancer: A Phase II Study of Panitumumab (PmAb) and Pembrolizumab (Pembro) in Combination With Neoadjuvant Chemotherapy (NAC) in Patients With Newly Diagnosed Triple Negative Inflammatory Breast Cancer (TN-IBC)
Enrollment Status: Withdrawn
Publish Date: October 24, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Phase IIB Study of Neoadjuvant ZT Regimen (Enzalutamide Therapy in Combination With Weekly Paclitaxel) for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer
A Phase IIB Study of Neoadjuvant ZT Regimen (Enzalutamide Therapy in Combination With Weekly Paclitaxel) for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Procedure, Other, Drug
Study Drugs: Enzalutamide, Paclitaxel
Study Phase: Phase 2
Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Other, Behavioral
P3 Efficacy Evaluation of Enobosarm in Combo With Abemaciclib Compared to Estrogen Blocking Agent for 2nd Line Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on an Estrogen Blocking Agent Plus Palbociclib
P3 Efficacy Evaluation of Enobosarm in Combo With Abemaciclib Compared to Estrogen Blocking Agent for 2nd Line Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on an Estrogen Blocking Agent Plus Palbociclib
Enrollment Status: Terminated
Publish Date: February 26, 2024
Intervention Type: Drug
Study Drugs: Enobosarm, Abemaciclib, Non-steroidal AI or steroidal AI or Fulvestrant
Study Phase: Phase 3
An Open-label Phase 1b Study of ORIC-101 in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors
An Open-label Phase 1b Study of ORIC-101 in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: December 15, 2023
Intervention Type: Drug
Study Phase: Phase 1
Harvest of Circulating Tumor Cells (CTCs) From Patients With Metastatic Breast Cancer (MBC) Using the Parsortix™ PC1 System
Harvest of Circulating Tumor Cells (CTCs) From Patients With Metastatic Breast Cancer (MBC) Using the Parsortix™ PC1 System
Enrollment Status: Completed
Publish Date: June 05, 2023
Intervention Type: Diagnostic test
A Phase II Study Using Talimogene Laherparepvec for Inflammatory Breast Cancer (IBC) or Non-IBC Patients With Inoperable Local Recurrence
A Phase II Study Using Talimogene Laherparepvec for Inflammatory Breast Cancer (IBC) or Non-IBC Patients With Inoperable Local Recurrence
Enrollment Status: Terminated
Publish Date: January 25, 2023
Intervention Type: Biological, Other
Study Drug: Talimogene Laherparepvec
Study Phase: Phase 2
Phase II Study of Denosumab to Define the Role of Bone Related Biomarkers in Breast Cancer Bone Metastasis
Phase II Study of Denosumab to Define the Role of Bone Related Biomarkers in Breast Cancer Bone Metastasis
Enrollment Status: Terminated
Publish Date: November 22, 2019
Intervention Type: Drug
Study Phase: Phase 2
Phase I and Phase I Trastuzumab Cohort Study of Entinostat, Lapatinib and Trastuzumab in Patients With HER2-Positive Metastatic Breast Cancer in Whom Trastuzumab Has Failed
Phase I and Phase I Trastuzumab Cohort Study of Entinostat, Lapatinib and Trastuzumab in Patients With HER2-Positive Metastatic Breast Cancer in Whom Trastuzumab Has Failed
Enrollment Status: Completed
Publish Date: May 20, 2019
Intervention Type: Biological, Drug, Other
Study Phase: Phase 1
View 13 Less Clinical Trials

399 Total Publications

Dual Therapeutic Impact of AXL Inhibitor AB-329: Chemotherapy Sensitization and Immune Microenvironment Reprogramming in TNBC.
Dual Therapeutic Impact of AXL Inhibitor AB-329: Chemotherapy Sensitization and Immune Microenvironment Reprogramming in TNBC.
Journal: International journal of molecular sciences
Published: July 09, 2025
Similar Doctors
Expertise in
13
conditions
Dr. Michael E. Carney
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
13
conditions
Dr. Michael E. Carney
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Kapiolani Medical Specialists

1319 Punahou St, 
Honolulu, HI 
 (0.1 miles away)
808-983-6000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Carney is a Gynecologic Oncologist and an Oncologist in Honolulu, Hawaii. Dr. Carney is highly rated in 13 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Oophorectomy, and Hysterectomy. Dr. Carney is currently accepting new patients.

Expertise in
4
conditions
Dr. Jami A. Fukui
Oncology
Expertise in
4
conditions
Dr. Jami A. Fukui
Oncology

University Clinical Education And Research Associates

98 -1079 Moanalua Rd, 
Aiea, HI 
 (8.9 miles away)
808-486-6000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jami Fukui is an Oncologist in Aiea, Hawaii. Dr. Fukui is highly rated in 4 conditions, according to our data. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Angiosarcoma. Dr. Fukui is currently accepting new patients.

Expertise in
35
conditions
Dr. Shaun C. Donegan
Oncology
Expertise in
35
conditions
Dr. Shaun C. Donegan
Oncology

Queens University Medical Group

1380 Lusitana St, Suite 913, 
Honolulu, HI 
 (1.4 miles away)
808-691-8521
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Shaun Donegan is an Oncologist in Honolulu, Hawaii. Dr. Donegan is highly rated in 35 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, Large-Cell Lung Carcinoma, and Squamous Cell Lung Carcinoma. Dr. Donegan is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ueno's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile